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Abstract 
Stealth pH-responsive liposomes for the delivery of therapeutic proteins to the bladder 
epithelium were prepared using methoxy-poly(ethylene glycol)5kDa-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine (mPEG5kDa-DSPE) and stearoyl-poly(ethylene glycol)-
poly(methacryloyl sulfadimethoxine) copolymer (stearoyl-PEG-polySDM), which 
possesses an apparent pKa of 7.2. Liposomes of 0.2:0.6:100, 0.5:1.5:100 and 1:3:100 
mPEG5kDa-DSPE/stearoyl-PEG-polySDM/(soybean phosphatidylcholine + cholesterol)  
molar ratios were loaded with bovine serum albumin (BSA) as a protein model. The 
loading capacity was 1.3% w/w BSA/lipid. At pH 7.4, all liposome formulations 
displayed a negative zeta-potential and were stable for several days at pH 7.4. By pH 
decrease or addition to mouse urine, the zeta potential strongly decreased, and the 
liposomes underwent a rapid size increase and aggregation. Photon correlation 
spectroscopy (PCS) and transmission electron microscopy (TEM) analyses showed that 
the extent of the aggregation depended on the stearoyl-PEG-polySDM/lipid molar ratio. 
Cytofluorimetric analysis and confocal microscopy showed that at pH 6.5, the incubation 
of MB49 mouse bladder cancer cells and macrophages with fluorescein isothiocyanate-
labelled-BSA (FITC-BSA) loaded and N-(Lissamine Rhodamine B sulfonyl)-1, 2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt (rhodamine-
DHPE) labelled 1:3:100 mPEG5kDa-DSPE/stearoyl-PEG-polySDM/lipid molar ratio 
liposomes resulted in a time-dependent liposome association with the cells. At pH 7.4, 
the association of BSA-loaded liposomes with the MB49 cells and macrophages was 
remarkably lower than at pH 6.5. Confocal images of bladder sections revealed that 2 h 
after the instillation, liposomes at pH 7.4 and control non-responsive liposomes at pH 7.4 
or 6.5 did not associate nor delivered FITC-BSA to the bladder epithelium. On the 
contrary, the pH-responsive liposome formulation set at pH 6.5 and soon administered to 
mice by bladder instillation showed that, 2 h after administration, the pH-responsive 
liposomes efficiently delivered the loaded FITC-BSA to the bladder epithelium. 
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1. Introduction 
Bladder cancer is the fifth most common malignancy in the world with non-muscle-
invasive bladder cancer comprising 70% of newly diagnosed bladder cancers [1]. The 
gold standard treatment of this neoplasia in the early stages is a trans-urethral resection 
followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). 
However, a large fraction of patients does not respond to the treatment, and severe side 
effects are associated to this therapy [2]. Therefore, alternative or complementary 
strategies for the management of non-muscle-invasive bladder cancer are needed [3]. 
Among the biological therapies, Interferon-alpha (IFN-) has been successfully applied 
in initial early-phase clinical studies, especially in combination with BCG 
immunotherapy [4]. Atezolizumab is a humanized antibody recently approved by FDA 
for bladder cancer treatment [5] while the 38 kDa immunomodulator PstS1 obtained from 
the Mycobacterium tuberculosis is currently under clinical trials [6]. In the recent past, 
the neutrophil-activating protein (HP-NAP) produced by the bacterium Helicobacter 
pylori has been shown to inhibit bladder cancer growth in a mouse model [7]. However, 
the low residence time of a therapeutic biologic in the bladder, which mainly does not last 
beyond the first bladder emptying, requires large doses and frequent instillations to 
achieve a therapeutic effect.  
Several efforts have been devoted to generate drug delivery systems to target bladder 
cancer, including gold nanoparticles [8], mucoadhesive cationic particles [9-12], gelatine-
based nanosystems [13,14], and albumin-based nanoparticles [15]. Liposomes have never 
been explored for the delivery of proteins and peptides for treatment of bladder cancer 
[16]. On the other hand,  they have been successfully used to deliver peptides, synthetic 
lipopeptides and proteins for a variety of applications including: vaccination [17], cell-
targeting and intracellular delivery [18,19], cell activation [20], imaging [21,22], 
theranostic applications [23], treatment of cerebrovascular diseases [24], ocular 
inflammation [23], pulmonary artery hypertension [25], restenosis [26], lysosomal 
storage diseases [27,28], and cancer [29]. Notably, liposomes have been considered as 
vehicle for local administration of BCG [30,31] and anticancer drugs for the treatment of 
bladder cancer [32,33] as well as for the treatment of a variety of urinary tract disorders 
such as interstitial cystitis/painful bladder syndrome [34], haemorrhagic cystitis [35] and 
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refractory overactive bladder [36]. Moreover, liposomes do not alter the urothelium in 
comparison to other delivery systems, such as micelles [37].  
In a previous study, we reported the preparation of biocompatible pH-responsive 
liposomes that, upon exposure to acidic pH, underwent aggregation due to the loss of 
surface charge and associated with cells [38]. This behaviour provides for the liposomal 
selective response to acidic environments, such as in solid tumours [39] or in the bladder 
cavity [40]. In this study, we investigated the biophysical properties of a pH sensitive 
liposome formulation and explored it as delivery vehicle of proteins to macrophages, 
cancer cells and epithelium of the bladder with the aim to put forward an alternative to 
the existing standard of care for bladder cancer treatment (namely BCG) [41] that may 
cause harsh local inflammation and bacterial infection [42]. The responsive system we 
discuss here, in virtue of its epithelium adhesive properties, may enhance the outcome of 
therapeutic proteins when locally administered by increasing the exposure time of the 
bladder epithelium and the local bioavailability.  
 
2. Materials and methods 
Cholesterol, 4.67 kDa polyoxyethylene stearyl ether (Brij-700
®
), foetal bovine serum 
(FBS) and Float-A-Lyzer® G2 300 kD molecular weight cut-off  (MWCO) dialysis 
devices were provided by Sigma-Aldrich (St. Louis, MO, USA). Soybean 
phosphatidylcholine (Epikuron 200, SPC) was furnished by Cargill (Minneapolis, MN, 
USA). Methoxy-poly(ethylene glycol)5kDa-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (ammonium salt) (mPEG5kDa-DSPE) resulting from the 
condensation of 5 kDa methoxy-poly(ethylene glycol)-COOH and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine was purchased from JenKem Technology USA, Inc. 
(Allen, TX, USA), and N-(Lissamine Rhodamine B sulfonyl)-1, 2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine, triethylammonium salt (rhodamine-DHPE) was 
obtained from VWR International PBI (Radnor, PA, USA). Alexa Fluor 647-Cholera 
Toxin Subunit B was purchased from Molecular Probes (Waltham, MA, USA). Stearoyl-
PEG-polySDM and fluorescein isothiocyanate labelled bovine serum albumin (FITC-
BSA) were synthetized as previously described [38,43]. The chemical structures of lipids 
and of lipid conjugates are reported in Scheme S1.  
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Sterile 0.2 µm PTFE Millex® syringe filters and 0.2 µm PES Corning® syringe filters 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). All buffer salts, other 
reagents and solvents were purchased from VWR International PBI (Radnor, PA, USA), 
Sigma-Aldrich (St. Louis, MO, USA) and J.T. Baker (Phillipsburg, NJ, USA) and were 
of analytical or HPLC grade unless stated otherwise. All the reagents used for cell studies 
(unless indicated) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
2.1. Liposome preparation and protein loading studies  
BSA-loaded liposomes were prepared using a 2:1 soybean 
phosphatidylcholine/cholesterol molar ratio lipid mixture according to the thin layer 
rehydration technique [44]. Formulations were prepared using 5 or 10 mg/mL lipid 
concentrations and 0.2, 0.5, 1 or 2 mg/mL BSA according to the procedure previously 
described [38]. Briefly, 5 or 10 mg of lipids were dissolved in 3 mL of anhydrous 
chloroform. The lipid solution was filter-sterilized using 0.2 µm PTFE Millex® syringe 
filters. The organic solvent was removed under reduced pressure using a rotary 
evaporator and stored overnight under vacuum. A 20 mg/mL BSA stock solution in PBS 
at pH 7.4 was filter-sterilized using 0.2 µm PES Corning® syringe filters. The BSA 
content in the solution was assessed by UV-Vis spectroscopy and UPLC 
chromatography. The lipid film was rehydrated with 100 μL of a 2, 5, 10 or 20 mg/mL 
BSA solution in PBS at pH 7.4 and processed with 10 freeze-thawing cycles. The 
samples were then diluted to 1 mL with the same buffer and finally extruded 11 times 
through a polycarbonate membrane with a 200-nm cut-off (Nuclepore, Pleasanton, CA, 
USA). The non-loaded BSA was removed by dialysis according to a validated protocol 
[45]; 1 mL of liposomes was dialyzed using a 300-kDa Float-A-Lyser
®
 G2 system 
against 1 L of PBS at pH 7.4. The liposome loading efficiency and capacity were 
assessed after dialysis by reverse phase ultra-performance liquid chromatography (UPLC, 
Agilent, Santa Clara, CA, USA) equipped with a Phenomenex ZORBAX RRHD column 
(150 x 2.1 mm) loaded with stationary phase Eclipse Plus C18 (Dikma, Lake Forest, CA, 
USA) and isocratically eluted at 0.2 mL/min with a 90:10 v/v mixture of H2O/acetonitrile 
both supplemented with 1% v/v of formic acid. The UV detector was set at 220 nm. The 
BSA concentration (y) was determined from the peak area (x) using a standard curve 
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obtained with BSA solutions of known concentrations [y (μg BSA/mL) = 0.0178 x (peak 
area) – 5.3054; R2 = 0.99979]. The encapsulation efficiency was calculated as the amount 
of loaded BSA after dialysis and expressed as the percentage of the BSA fed to hydrate 
the liposomes. The liposome loading capacity was expressed as the amount of 
encapsulated BSA (after dialysis) per mg of lipid. 
PEGylated liposomes were prepared using 10 mg of lipids and 1 mg BSA according to 
the procedure reported above to obtain a final volume of 1 mL. A 8 mg/mL mPEG5kDa-
DSPE solution in PBS, pH 7.4, was filter-sterilized using 0.2 µm PES Corning® syringe 
filters and was added to the lipid vesicles to obtain 0.2:100, 0.5:100, and 1:100 
mPEG5kDa-DSPE/lipids mol%. Liposomes were dialyzed as reported above to remove the 
non-encapsulated BSA, and the liposome loading efficiency and capacity were evaluated.  
A 25 mg/mL stock solution of stearoyl-PEG-polySDM in PBS, pH 7.4 was filter-
sterilized using 0.2 µm PES Corning® syringe filters. Stealth pH-responsive liposomes 
(pH-RL) were prepared by adding proper volumes of the stearoyl-PEG-polySDM stock 
solution to the mPEG5kDa-DSPE decorated liposomes described above to obtain: 
0.2:0.6:100, 0.5:1.5:100, or 1:3:100 mPEG5kDa-DSPE/stearoyl-PEG-polySDM/lipids 
mol% (0.2:0.6-pH-RL, 0.5:1.5-pH-RL and 1:3-pH-RL, respectively). The formulations 
were incubated at 37 °C for 1 h before proceeding with the experiments. 
Non-pH-responsive formulations used as control liposomes (0.2:0.6-CL, 0.5:1.5-CL and 
1:3-CL) were prepared as reported above for pH-RL by replacing the stearoyl-PEG-
polySDM with equimolar amounts of Brij-700
®
.  
Fluorescently double-labelled liposomes 1:3-pH-RL and 1:3-CL were prepared for cell 
treatments and in vivo tests by adding 0.1 mol% of rhodamine-DHPE (Biotium, 
Hayward, CA, USA) to the chloroform lipid mixture (10 mg/mL of lipids in the final 
liposome formulation). One mg/mL FITC-BSA in PBS, pH 7.4, was used to rehydrate the 
lipid films. Fluorescent liposomes were prepared as above. Rhodamine-DHPE-labelled 
liposomes containing non-labelled BSA and unlabelled liposomes loaded with FITC-
BSA were used as controls. 
All procedures were performed under sterile conditions. 
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2.2. Liposome characterization: size and zeta potential analysis and TEM imaging 
Size, polydispersity index (PDI) and zeta potential were measured by Photon correlation 
spectroscopy (PCS) using a Zetasizer NanoZS (Malvern Instruments Ltd., UK). Results 
of size analysis were expressed as Z-average. Liposome samples (0.5 mg/mL final lipid 
concentration) in PBS, pH 7.4, were analysed at days 0, 2, 5, 7, 9, 12, 16, 19 and 48 at 25 
°C and 37 °C. Liposome samples (0.5 mg/mL final lipid concentration) were prepared by 
20-fold dilution of the stock liposome suspension (10 mg/mL lipid concentration in PBS 
at pH 7.4) with PBS, pH 6.5 and 7.4, and were analysed at 0, 0.5, 1, 2, 4, 6 and 24 h at 25 
°C and 37 °C. Time “zero” corresponded to 1 min after pH setting. 
A size analysis of 1:3-CL and 1:3-pH-RL (0.5 mg/mL final lipid concentration), prepared 
by 20-fold dilution of the stock liposome suspension as reported above, was also carried 
out at different pHs ranging from 6.5 to 7.4 and in mouse urine.  
The zeta potential was determined applying a voltage of 40 V. 
A transmission electron microscopy (TEM) analysis was performed using a FEI Tecnai 
G2 microscope (Hillsboro, OR, USA). Liposomes (0.5 mg/mL final lipid concentration) 
in PBS, pH 7.4 and 6.5, were laid down on a carbon-coated copper grid at time 1 h. The 
excess volume was removed using filter paper, and the samples were negatively stained 
with 1% uranyl acetate in distilled water and analysed. 
 
2.3. Evaluation of protein release  
Two mL of each of the liposome formulations was transferred into a Float-A-Lyzer
®
 G2 
300 kDa MWCO dialysis device and placed in 1 L of PBS, pH 7.4 or 6.5 at 25 °C and 37 
°C. At 1, 2, 4, 6, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 h, aliquots of the liposome 
samples (100 µL) were withdrawn, and the BSA content was quantified by reverse phase 
UPLC analysis as described above. The amount of released BSA was calculated by 
subtracting the amount of BSA in the donor compartment (non-released BSA) from the 
initial amount in the dialysis device by referring to the standard titration curve reported 
above. 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2.4. Evaluation of liposome association to the cells  
MB49 mouse bladder cancer cells (kindly provided by Prof. Michael O’Donnell, 
University of Iowa, Iowa City, IA-USA) and THP-1 human monocytes (purchased from 
ATCC®) were grown in RPMI-1640 medium supplemented with 10% FBS. The MB49 
and THP-1 cells were seeded on 24-well plates (2×10
5 
per well). The THP-1 cells were 
differentiated to macrophages by adding 100 ng/mL phorbol 12-myristate 13-acetate 
(PMA) to the medium and left to differentiate for 48 h [46]. The medium was removed, 
and the cells were washed twice. NaHCO3-free DMEM-based medium supplemented 
with 10 mM Na2HPO4 and 4 mM HEPES was used to wash MB49 cells. PBS 
supplemented with 2 mg/mL glucose and 0.3 mg/mL glutamine was used to wash THP-1-
derived macrophages (TDM). The media were optimized to ensure cell viability and 
constant pH during the experiments. Next, the cells were incubated with 0.5 mg/mL of 
FITC-BSA-loaded rhodamine-DHPE labelled 1:3-CL or 1:3-pH-RL in minimum 
medium, pH 7.4 or 6.5, for 0.5, 1, 2, 4 and 6 h.  
BSA-loaded unlabelled liposomes, rhodamine-DHPE-labelled liposomes and FITC-BSA-
loaded unlabelled liposomes were used to define the fluorescence background and 
fluorescence leakage.  
Cytofluorimetric analyses. Cells were washed twice with PBS, collected by scraping, 
recovered by centrifugation and fixed with 3.7% (w/v) paraformaldehyde in PBS. The 
cells were then analysed using a BD FACSCanto instrument equipped with BD 
FACSDiva software (Becton Dickinson, Franklin Lakes, NJ, USA) and gated using 
forward vs. side scatter to exclude debris and dead cells. The double FITC- and 
rhodamine-stained cell population was analysed.  
Confocal microscopy. Cells were seeded on 24-chamber glass slides (Sigma–Aldrich, St. 
Louis, MO, USA). After the incubation with liposomes, the cells were washed twice with 
PBS and then fixed with 3.7% (w/v) paraformaldehyde in PBS. The cell membranes were 
labelled with 10 μg/mL of Alexa Fluor 647-Cholera Toxin Subunit B. The nuclei were 
stained with DAPI. A confocal analysis was performed using a Leica TCS SP5 II 
confocal laser-scanning microscope equipped with Leica HCX PL APO lambda blue 
40x/1.25 and 63x/1.4 OIL UV lenses and Leica Application Suite AF software (Leica 
Microsystems, Mannheim, Germany). Lasers at 405, 488, 560 and 633 nm were used to 
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detect the fluorescence of DAPI, FITC, rhodamine and Alexa Fluor 647, respectively and 
emission was recovered at a bandwidth centred at 461, 525, 580 and 660 nm, 
respectively. The localization of liposomes, BSA and cell membrane was derived by a 
line-scan analysis of single fluorophores (rhodamine, FITC, and Alexa Fluor 647) along a 
cellular section. The quantification of the co-localization between the fluorescent signal 
from rhodamine and that from FITC, per single cell, was also performed. At least 10 
fields were analysed for each condition. Image analyses were performed using ImageJ 
1.47v (National Institutes of Health software package). 
 
2.5. In vivo studies 
The in vivo studies were carried out using three-month-old female C57BL/6J mice. 
Mouse urine samples were obtained one week before the mice were treated with the 
liposome formulations. To this aim, mice were maintained in a metabolic cage overnight 
(12 h) with ad libitum access to food and water, and the urine was collected. 
Before the liposome administration, the mice were anesthetized by intra-peritoneal 
injection of a Zoletil (Virbac, Carros cedex, France) and Xylazine (VetTech, Middleburg, 
VA, USA) mix (40 mg/Kg and 5 mg/Kg, respectively) and catheterized via the urethra 
with a 24-gauge plastic intravenous cannula. Bladders were washed with PBS at pH 7.4 
or 6.5 as appropriate and then instilled with 150 μL of the liposome formulation (10 
mg/mL final lipid concentration) at pH 6.5 and 7.4, 1 min after the pH was set, when 
required, with 1 N HCl addition. The mice were divided in 4 groups (N=3 for each group) 
and the bladders were instilled with FITC-BSA-loaded rhodamine-DHPE-labelled 
liposomes: 1:3-pH-RL at pH 7.4; 1:3-pH-RL at pH 6.5; 1:3-CL at pH 7.4; 1:3-CL at pH 
6.5. The formulations were instilled through the cannula and maintained within the 
bladder for 2 h to prevent premature bladder evacuation. The bladder contents were 
carefully removed, and the cavities were washed twice with 150 μL PBS at pH 7.4 or 6.5. 
The mice were euthanized by cervical dislocation, and the bladders were excised and 
embedded in Optimal Cutting Temperature Tissue Freezing Medium. The specimens 
were cut with a cryostat Leica CM1850 (Leica Microsystems, Mannheim, Germany) to 
obtain 4 μm thick histological sections. The slices were mounted and analysed by 
confocal microscopy as described above. 
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The mice were handled by specialized personnel under the control of inspectors of the 
Veterinary Service of the Local Sanitary Service. All in vivo procedures were carried out 
according the EU and NIH directives and approved by the Italian Ministry of Health 
(authorization number 54/2014).  
 
2.6. Statistical analysis 
Data were processed using either a two-tailed unpaired Student’s t test or analysis of 
variance (ANOVA), followed by either Bonferroni or, when necessary, Games–Howell 
post hoc test (SPSS statistical software; IBM, Armonk, NY). Levene’s test was used to 
determine homogeneity of variances. Values of p ≤ 0.05 were considered statistically 
significant. 
 
3. Results 
3.1. Evaluation of liposome loading capacity 
The preliminary studies were aimed at selecting suitable conditions for the preparation of 
protein-loaded liposome formulations. BSA was used as protein model, and the effect of 
the lipid/protein ratio on the protein loading efficiency and capacity was investigated. 
Data reported in Figure 1 show that the loading efficiency decreased and the loading 
capacity increased as the protein concentration in the rehydrating buffer increased, as 
reported in the literature [47]. The maximal loading efficiency (13 µg BSA/mg lipids) 
was obtained with a 10 mg/mL lipid concentration and a 0.2 mg/mL BSA concentration 
in the rehydrating buffer (Figure 1A), while the maximal loading capacity was obtained 
with 2 mg/mL BSA (Figure 1B).  
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Figure 1. Effect of lipid and BSA concentration in the rehydrating buffer on 
encapsulation efficiency (A) and capacity (B) of the protein in liposomes. Liposomes 
were generated at lipid concentrations of 5 (□) and 10 (■) mg/mL. * p <0.05 refers to the 
formulations obtained with 10 mg/mL lipids vs 5 mg/mL lipids at each BSA 
concentration. 
 
 
According to these results and to the evidence that a higher protein concentration in the 
rehydrating buffer required a longer dialysis to remove the non-loaded BSA, the 
liposomal formulation obtained by rehydrating lipids at 10 mg/mL with a buffer 
containing 1 mg/mL BSA was selected.  
The BSA quantification after dialysis (Figure S2 A, B, C and D) showed that the post-
insertion of mPEG5kDa-DSPE and stearoyl-PEG-polySDM to the liposomal formulation 
did not affect the protein payload.  
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3.2. Liposome size analysis and effect of pH 
pH-responsive liposomes with the following composition were generated and analysed: 
0.2:0.6:100, 0.5:1.5:100, and 1:3:100 mPEG5kDa-DSPE/stearoyl-PEG-polySDM/lipids 
mol% (0.2:0.6-pH-RL, 0.5:1.5-pH-RL and 1:3-pH-RL, respectively). Control liposomes 
had the following composition: 0.2:0.6:100, 0.5:1.5:100, or 1:3:100 mPEG5kDa-
DSPE/Brij-700
®/lipids mol% (0.2:0.6-CL, 0.5:1.5-CL and 1:3-CL, respectively). 
Size analyses of BSA-loaded pH-RL were performed by dynamic light scattering (DLS) 
at pH 7.4 and at pH 6.5 to mimic the human urine. Figure 2A, C and E, and 
supplementary Figure S3A, C and E show that at pH 7.4 the preparation process, 
including freeze-thaw, extrusion and incubation at 37 °C [44], yielded 0.2:0.6-pH-RL, 
0.5:1.5-pH-RL and 1:3-pH-RL liposomes with size of 287 ± 10.7 nm (PDI 0.5 ± 0.07), 
235 ± 8.4 nm (PDI 0.2 ± 0.04), and 167 ± 1.6 nm (PDI 0.2 ± 0.03), respectively. After 30 
min exposure to acidic pH, both the mean size and PDI of all formulations considerably 
increased. Liposomes were considered to be in the aggregated state when size exceeded 
1000 nm or PDI was 1. This occurred for the 0.5:1.5 and 1:3 pH-RL after 30 min 
incubation at pH 6.5. At pH 6.5, the 0.2:0.6-pH-RL and 0.5:1.5-pH-RL liposomes 
reached the maximum size in 1-2 h incubation, while the 1:3-pH-RL formulation showed 
a progressive size increase up to several µm in 6 h. Notably, under these conditions, the 
size increase profile of the liposomes depended on the mPEG5kDa-DSPE/stearoyl-PEG-
polySDM/lipids molar ratio. For example, after 2 h incubation at pH 6.5 the size of 
0.2:0.6-pH-RL, 0.5:1-pH-RL and 1:3-pH-RL liposomes was 755 ± 289 nm (PDI 0.92 ± 
0.07), 2,069 ± 436 nm (PDI 0.86±0.28) and 3,602 ± 844 nm (PDI 1), respectively. The 
size increase paralleled a significant PDI increase, which indicates that under these 
conditions the lipid vesicles underwent macroscopic and inhomogeneous structural 
alterations. 
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Figure 2. Time course of the size profile of 0.2:0.6-pH-RL (A), 0.2:0.6-CL (B), 0.5:1.5-
pH-RL (C), 0.5:1.5- L (D), 1:3-pH-RL (E), and 1:3-CL (F) in PBS at pH 7.4 (□) and 6.5 
(■) at 25 °C. “as”: aggregated state. * p <0.05 refers to formulations incubated at pH 6.5 
vs pH 7.4 at each time point. 
 
Non-pH-responsive control liposomes (CL) obtained using Brij-700
®
 instead of the pH-
responsive stearoyl-PEG-polySDM copolymer did not undergo size and PDI alterations 
upon exposure to acidic pH. Figure 2B, D and F, and supplementary Figure S2B, D and F 
show that the sizes ranged from 146 ± 1.2 nm to 223 ± 3.7 nm and PDIs ranged from 0.12 
± 0.04 to 0.35 ± 0.03. 
The time course size profiles of the 1:3-pH-RL formulation in the pH range of 7.4-6.5 
depicted in Figure 3A show that these liposomes underwent an immediate size increase 
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as the pH was lowered below 6.7. The pH conditions close to neutrality (7.0 and 7.2) 
required at least 6 h to induce liposome aggregation (Figure 3A). Notably, the figure 
shows that these liposomes also underwent a size increase in the mouse urine with a 
similar profile to that observed in acidic buffer while the 1:3-CL formulation did not 
show size alterations when exposed to urine. 
 
 
Figure 3. Time course of the size profile of 1:3-pH-RL in PBS at pH ranging from 7.4 to 
6.5 (A) and of 1:3-CL (□) and 1:3-RL (■) in mouse urine (B) at 25 °C. Panel A: *p <0.05 
refers to the formulation at specific time point vs time zero at the same pH; panel B: * p 
<0.05 refers to formulations incubated at pH 6.5 vs pH 7.4 at each time point. 
 
Figures 4A, B and C report the long term stability profiles of all pH-responsive and 
control vesicles at pH 7.4. The size of CL remained approximately of 200 nm for 16 days 
regardless of the mPEG5kDa-DSPE/Brij-700
®
/lipid molar ratio composition. The size of 
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the 0.2:0.6-pH-RL and 1:3-pH-RL formulations was stable up to 12 days and increased to 
approximately 500 nm after 16-20 days, while the size of 0.5:1.5-pH-RL increased to 
approximately 500 nm in 5 days. 
 
 
Figure 4. Time course of the size profile of pH-responsive liposomes (pH-RL: ▲) and 
control liposomes (CL: ●) for the 0.2:0.6-pH-RL and 0.2:0.6-CL formulations (A), 
0.5:1.5-pH-RL and 0.5:1.5-CL formulations (B), and 1:3-pH-RL and 1:3-CL 
formulations (C) in PBS at pH 7.4 at 25 °C. * p <0.05 refers to the formulation at specific 
time point vs time zero.  
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3.3. Liposome zeta potential in response to pH  
At pH 7.4, the pH-RL liposomes displayed a negative zeta potential. Figure 5A shows 
that the absolute zeta potential value increased as the stearoyl-PEG-polySDM density on 
the liposome surface increased and significantly decreased to nearly neutrality when the 
liposomes were incubated at pH 6.5, regardless the composition.  
 
 
Figure 5. Zeta potential of the three pH-RL formulations (A) and CL formulations (B) in 
PBS at pH 7.4 (□) and 6.5 (■). * p <0.05 refers to each formulation at pH 6.5 vs pH 7.4.  
 
This behaviour was in fair agreement with the results reported in the literature for similar 
systems [48,49]. Figure 5B shows that the zeta potential of control liposomes reflected 
the neutral character of the Brij-700
®
 on the vesicle surface. Indeed, CL formulations 
displayed nearly neutral zeta potential, regardless of the polymer/lipid composition and a 
slight decrease of the absolute values when the pH shifted from 7.4 to 6.5. The 1:3-pH-
RL and 1:3-CL in mouse urine displayed a zeta potential value of -0.59 ± 0.35 and of 
0.03 ± 0.45, respectively, confirming that the responsive liposomes possess a nearly 
neutral zeta potential in mouse urine. 
 
3.4. TEM imaging of liposomes 
The TEM images of pH-RL and CL at pH 7.4 and 6.5 reported in Figure 6 confirm the 
results obtained by DLS.  
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Figure 6. TEM images of the liposome formulations at pH 7.4, pH 6.5 and mouse urine. 
The mPEG5kDa-DSPE/stearoyl-PEG-polySDM composition for pH-RL and the 
mPEG5kDa-DSPE/Brij-700
®
 composition for CL are reported on the top-line of the figure. 
The size bar corresponds to 500 nm.  
 
At neutral pH, small separate pH-RL particles were observed. At acidic conditions, the 
vesicles underwent size increase and aggregation. As the stearoyl-PEG-polySDM density 
increased on the liposome surface, the formation of macroaggregates became more 
pronounced. Neither the particle size increase nor the aggregation was instead observed 
with CL at all tested surface Brij-700
®
 densities and pH conditions.  
 
3.5. Protein release  
The protein release profiles reported in Figure 7 were obtained by liposome dialysis. The 
BSA release was negligible within the first 6 h of incubation irrespective of the pH and 
liposome composition. Approximately 50% of the loaded BSA was released in 24 h by 
the 0.2:0.6-CL and 0.2:0.6-pH-RL while all other liposome formulations released 
approximately 35% of the loaded BSA; however, the difference was not statistically 
significant. In any case, the BSA release was complete in about 10 days. 
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Figure 7. BSA release profiles from 0.2:0.6-pH-RL formulations (A), 0.5:1.5-pH-RL 
formulations (B), and 1:3-pH-RL (C) in PBS at pH 7.4 (▲) and 6.5 (●) at 25 °C. The 
BSA release at each time point at pH 7.4 vs pH 6.5 was not statistically different.  
 
 
3.6. Interaction of liposomes with the cells  
The pH-dependent ability of the pH-RL liposomes to associate to cells was investigated 
using bladder cancer cells (MB49) and macrophages, which are crucial modulators of the 
tumour microenvironment [50]. The study was carried out by flow cytometry and 
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confocal microscopy using double fluorescent 1:3-CL and 1:3-pH-RL formulations to 
trace both the protein and the carrier.  
The cytofluorimetric data reported in Figure 8A and B show that after 6 h of incubation at 
pH 6.5 with 1:3-pH-RL, 57% of MB49 cells and 90% of THP-1-derived macrophages 
(TDM) were positive for BSA-loaded liposomes. The cell association of pH-RL at pH 7.4 
was significantly lower than that observed at acidic pH for both cell lines. Non-
responsive control liposomes yielded very low association at both pHs.   
 
 
 
Figure 8. Time-dependent association of FITC-BSA-loaded rhodamine-DHPE liposomes 
to MB49 cells (A) and TDM (B): incubation was performed with 1:3-CL at pH 7.4 (□) 
and 6.5 (■) and with 1:3-pH-RL formulations at pH 7.4 (■) and 6.5 (■). * p <0.05 refers 
to pH-RL at pH 6.5 vs pH 7.4 at each time point. 
 
Confocal microscopy showed the localization of the pH-sensitive FITC-BSA-loaded 
liposomes at the cellular level and confirmed the cytofluorimetric data. The pH-RL 
liposomes associated more rapidly to TDM cells than to MB49 cells, and the association 
was favoured by the acidic pH. Figure 9A and B show that after 6 h of incubation, the 
liposomes were detected inside the TDM cells, probably within the phagosomes, whereas 
they remained associated to the plasma membrane of MB49 cells. These results were 
confirmed by line-scanning analysis of cells (Figure 9C and E). The results reported in 
Figure 9D and F of the double stained pH-RL liposomes associated to a single cell 
definitively confirmed that TDM cells internalized the liposomes more efficiently than 
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MB49, and the pH-RL liposomes association profile in both cell lines was significantly 
favoured by acidic pH. 
 
Figure 9. Confocal microscopy images of MB49 cells (A) and TDM (B) treated with 0.5 
mg/mL of FITC-BSA-loaded rhodamine-DHPE labelled 1:3-pH-RL at pH 7.4 and 6.5 for 
1 h (upper panels) and 6 h (lower panels). The images were acquired using the 580 nm 
channel for rhodamine-DHPE detection (red), the 525 nm channel for FITC-BSA 
detection (green), the 461 nm channel for nuclei detection (blue), and the 660 nm channel 
for cell membrane detection (purple). The yellow signal results from merging the red and 
green signals. A magnified image from the merging is shown in the last column of each 
panel. The localization of liposomes (red profile), BSA (green profile) and cell membrane 
(purple profile), reported in panel C and E, was determined by line-scanning analysis 
along the white dotted axis in the merged bottom right images of panel A and B. The 
quantification of the red and green co-localized signals per MB49 cell (D) and TDM cell 
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(F) was obtained from images of cells incubated at pH 7.4 (□) and 6.5 (■) and expressed 
as arbitrary unit (a.u.). At least 10 fields (with an average of 80 cells per field) were 
analysed per each condition. * p < 0.05 refers to pH-RL at pH 6.5 vs pH 7.4 at each time 
point. 
 
Finally, neither significant cell association nor protein delivery was observed with CL 
liposomes at all experimental incubation times and pH (supplementary Figure S4).  
 
3.7.  In vivo studies 
The ability of pH-responsive liposomes to bind the bladder epithelium was evaluated by 
intra-bladder instillation to mice of FITC-BSA-loaded rhodamine-DHPE labelled 1:3-pH-
RL or 1:3-CL. Figure 10 reports representative confocal fluorescence microscopy images 
of a cross-section of the bladder of a mouse treated with pH-RL at pH 6.5. The white 
square in panel A highlights the region magnified in panels B-D where the liposomes 
appear massively associated to the bladder epithelium. The yellow labelled tissue areas in 
panels A and B result from merging the fluorescent signals of FITC-BSA and rhodamine-
labelled pH-RL.  
 
 
Figure 10. Microscopic examination of mice bladder cross-sections after installation of 
FITC-BSA-loaded Rhodamine-DHPE labelled liposomes (1:3-pH-RL) at pH 6.5. The 
nuclei were stained with DAPI, and the tissue was analysed by confocal fluorescence 
microscopy. The images were acquired using the 580 nm channel for rhodamine-DHPE 
detection (red), the 525 nm for FITC-BSA detection (green) and the 461 nm channel for 
nuclei detection (blue). The yellowish-green signal results from merging the red and 
green signal (panel A and B). A magnified image of the white square of image A is 
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shown in panel B and the corresponding green channel and red channel are depicted in 
panel C and D, respectively.  
 
The histological analysis of a 4 m thick bladder cross-section showed that the pH-
responsive liposome aggregates span a quite large epithelium surface. No liposomal 
association to the bladder epithelium was detected when pH-RL was administered at pH 
7.4 or when CL was injected into the mice bladders at pH 7.4 and 6.5 (data not shown). 
The results showed that the pH-RL efficiently deliver BSA to the epithelium when 
inoculated in the mouse bladder at pH 6.5.  
 
4. Discussion 
The study was inspired by the need to provide a prolonged exposure of the bladder 
epithelium to the biotherapeutics currently under investigation, such as IFN- and HP-
NAP of Helicobacter pylori [4,7], upon local instillation. The pH sensitive pH-RL 
liposomes described here were designed to respond to the conditions of the bladder 
lumen with the aim to enhance the liposome bioadhesion and the delivery of 
biotherapeutic payloads to the bladder epithelium by preventing the rapid drug clearance 
due to bladder emptying. 
The pH sensitive liposomes were obtained by decoration with a stearoyl-PEG-polySDM 
moiety, which was previously demonstrated to reversibly switch from the hydrophilic to 
the hydrophobic state by pH changes in the physiopathological range conditions [38]. 
The stearoyl-PEG-polySDM bioconjugate containing 7 methacryloyl sulfadimethoxine 
monomers was considered suitable to the aim of the work since it is responsive to the 
urine pH. Indeed, the hepta-SDM stearoyl-PEG conjugate has an apparent pKa of 7.2, 
which yields a LogD of 15.00 and 17.87 at pH 7.4 and pH 6.5, respectively [48], and 4.3 
and 1 charged SDM monomers on each stearoyl-PEG-polySDM unimer at 7.4 and 6.5, 
respectively. Therefore, the pH decrease from pH 7.4 to 6.5 results in an uncharged 
hydrophobic liposome surface. The composition of the liposomes was selected on the 
basis of previous results [51]. This study showed that the addition of mPEG5kDa-DSPE 
enhanced the overall liposome stability at pH 7.4, which is a requisite for their storing 
and handling. Brij-700
®
 was selected to produce control stealth liposomes in virtue of its 
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non-charged feature and hydrophilicity (LogP 9.09) in a wide physiological pH range and 
its comparable length to the stearoyl-PEG-polySDM copolymer. 
The protein loading capacity and efficiency preliminarily investigated to select suitable 
conditions to load a protein model (BSA) in liposomes were in fair agreement with the 
literature: the loading capacity increased and the efficiency decreased as the protein/lipid 
w/w feed ratio increased [47]. The liposome formulation obtained at 10 mg/mL lipid and 
rehydrated with 1 mg/mL BSA containing buffer was finally selected, taking into account 
the liposome extrusion process feasibility, and to balance the protein loading and the time 
required for the removal of non-loaded protein by dialysis.  
The liposome decoration with mPEG5kDa-DSPE and stearoyl-PEG-polySDM did not alter 
the loading capacity or the lipid bilayer permeability. However, both the protein loading 
and the surface decoration with the polymers affected the liposome size. The mPEG5kDa-
DSPE- and stearoyl-PEG-polySDM-decorated BSA-loaded formulations displayed a 
slightly larger size than their non-BSA loaded (BSA-free) counterparts described in our 
previous work [38]. The effect of the polymer decoration, already observed with similar 
formulations [47], may be ascribed to a different rearrangement of the lipid bilayer with 
embedded BSA, which can slightly affect the curvature of the liposomes. On the other 
hand, similar to what has been reported in the literature [52-54], the size of liposomes 
slightly decreased upon PEG decoration, probably as consequence of the dynamic 
structural rearrangement of the lipid bilayer. 
The zeta potential and size analysis studies (DLS and TEM) performed to evaluate the 
response of the liposomes when exposed to bladder-mimicking conditions (pH 6.5) 
highlighted the effect of the poly-SDM blocks of the pH-responsive polymer in 
controlling the colloidal properties of liposomes by pH changes. The environmental pH 
dictated the surface charge of pH-RL, while it had no effect on naked (data not shown) or 
CL liposomes. Indeed, these liposomes displayed an overall negative charge at pH 7.4, a 
condition that ensures repulsion and colloidal stability of the liposomes. The protonation 
of the sulfonamide group of the methacryloyl sulfadimethoxine monomers on the 
liposome surface at pH 6.5 remarkably decreased the zeta potential absolute value. The 
charge loss yielded a reduction of the repulsion forces and induced a hydrophobic 
liposome surface which, together, mediated the liposome aggregation and size 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
enlargement due to the formation of inter-vesicle intermingles involving the hydrophobic 
polySDM blocks. Inter-vesicle hydrophobic interactions of the polySDM blocks 
overcome residual anionic repulsive forces at pH 6.5. On the other hand, the Brij-700
®
 
used in control liposomes possesses a non-ionisable hydrophilic feature (LogP 9.09), 
which inhibits liposome aggregation by obstruction and steric repulsion, regardless the 
pH [55]. The size enlargement started soon after the pH was decreased from 7.4 to 6.5 
and achieved a plateau after approximately 1-2 h. The increase of the liposome PDI, a 
descriptor of the macroscopic response of the vesicles, at pH 6.5 indicates that, under 
these conditions, the lipid carrier underwent a heterogeneous macro-aggregation 
rearrangement. The TEM analysis confirmed that at an acidic pH (PBS at pH 6.5) and in 
urine the pH-RL underwent aggregation, which was directly proportional to the surface 
density of the poly-SDM blocks. According to the apparent poly-SDM pKa [56], the 
calculated percentage of charged SDM monomers at pH 7.4 and 6.5 was 61% and 14%, 
respectively. Consequently, the protonation and aggregation degree of pH-RL was found 
to increase as the pH stepwise decreased from 7.4 to 6.5. At pH 7.0 the pH-responsive 
liposomes underwent slower aggregation than at pH 6.5 (Figure 3A). The 6 h lag time 
before liposome aggregation observed at pH 7.0 can be ascribed to a lower LogD and 
higher charged/deprotonated ratio of methacryloyl sulfadimethoxine monomers than that 
calculated at pH 6.5, which slightly reduces the inter-vesicle intermingles involving the 
poly-SDM blocks. 
Because pH-RLs were designed for local instillation into the bladder, their structural 
behaviour when exposed to mouse urine was investigated. In urine, the aggregation of the 
liposomes showed a similar profile to that observed in PBS at 6.5 with a fast liposome 
size increase, indicating that the urine pH triggers the liposome association and the urine 
components do not inhibit the liposome response to the acidic environment. Furthermore, 
the aggregation profile of pH-responsive liposomes in mouse urine at pH 7.0 [57], was 
found to be more rapid compared to PBS at the same pH. Notably, mouse urine possesses 
a quite higher osmolality (2,317 ± 80 mOsmol/kg H2O) [58] with respect to PBS (280 - 
315 mOsm/kg H2O), which may favour hydrophobic interactions of the polySDM blocks 
on the liposome surface and thus a more rapid liposome aggregation under the same pH 
conditions. The aggregation was not observed for the control liposomes due to 
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permanently hydrophilic non-charged surface that provides for obstruction and steric 
repulsion at all pH tested [55]. The size reduction of liposomes observed at 6 h and 24 h 
in urine may be ascribed to the pH increase of urine that occurs over time [59]; such an 
increase promotes deprotonation of methacryloyl sulfadimethoxine monomers and partial 
liposome dissociation due to repulsive charges.  
The pH-RL and CL formulations showed good stability at pH 7.4 for up to 12 days 
without significant size or PDI alteration. Instability for both formulations at 12 days was 
quite similar and may occur because of the polymer detachment from the liposome 
bilayer over time. Only the 0.5:1.5-pH-RL formulation displayed an earlier size increase 
after 3 days. This may be ascribed to insufficient stearoyl-PEG-polySDM density to 
ensure adequate anionic charges (zeta potential is -5 mV) and repulsive forces at pH 7.4. 
Nevertheless, the stearoyl-PEG-polySDM density on the 0.5:1.5-pH-RL allows for 
sufficiently strong hydrophobic inter-vesicle interactions, the latter being instead too poor 
in the 0.2:0.6-pH-RL that have a lower polymer density. The liposomes showed similar 
long term stability profiles at 25 °C and 37°C. This behaviour can be explained by the 
fact that the lipid mixture used to produce the liposomes (soy 
phosphatidylcholine/cholesterol) possesses a low transition temperature (range -21°C to -
18 °C) [60], and thus the lipid bilayers are in the fluid state at both temperatures tested 
while the polymers behave similarly at the two temperatures. 
The protein release profile from the pH-RL formulations at 25 °C showed that neither the 
polymer coating nor the pH of incubation affected the release, thus, neither the liposome 
aggregation nor the structural changes of the polySDM blocks induced by acidic 
conditions significantly altered the membrane permeability of the vesicles. Furthermore, 
the protein release occurred in 10 days after 6 h lag time, allowing the carrier to associate 
to the biological target surface before a prolonged release takes place. According to the 
literature, the absence of burst release of BSA may be correlated to both interaction of the 
protein with the lipid components of the liposome bilayer and the low permeability of 
BSA through the lipid bilayer [61]. No significant difference in the BSA release profile 
was observed at 37 °C, which may be correlated to the fact that the lipid mixture used to 
prepare the liposomes is in a fluid state at both temperatures and the bilayer permeability 
does not change significantly between 25 °C and 37 °C [60]. 
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Based on the stability profile at neutral pH and the responsive behaviour to the intra-
bladder pH [40], the 1:3:100 mPEG5kDa-DSPE/stearoyl-PEG-polySDM/lipids molar ratio 
formulation was selected for the in vitro and in vivo biological studies.  
The association of the BSA-loaded liposomes was tested in vitro on MB49 urothelial 
carcinoma cells and PMA-differentiated THP-1 macrophages that do not possess a 
specific functional profile [62]. The MB49 cell line is an excellent model to study anti-
tumour agents [63]. Macrophages are crucial cells involved in the control of tumour 
progression [50]. Monocytes and macrophages are in fact recruited from the circulation 
into the tumours, where they actively participate to the carcinogenic process. Tumour-
associated macrophages have been related with poor clinical outcomes [50], while 
macrophage activation enhances the anti-tumour immune responses [64]. Studies 
performed to yield macrophage targeting have shown that the liposome uptake by 
macrophages depends on a variety of features, including size, charge and composition 
[65], although the macrophage heterogeneity has not allowed to extensively elucidate the 
impact of liposome features on the immune response [64,66]. We focused our 
investigation on assessing whether pH-RL underwent association to and engulfment by 
macrophages.  
The cytofluorimetric data showed that the association of pH-RL to both cell lines was 
remarkably higher in acidic conditions mimicking the urine than at pH 7.4. Under the 
acidic conditions in fact, the liposome surface charge is significantly decreased (absolute 
zeta potential decrease) and the surface hydrophobicity increases (LogD decrease); 
hence, the liposome aggregation and association with cells may occur. The pH-sensitive 
liposome association to macrophages at pH 7.4 may result from the surface anionic 
charges that the vesicles possess at this pH; in fact, negatively charged liposomes have 
been reported to be taken up at some extent by macrophages [65]. 
The confocal microscopy images showed that the uptake of the BSA-loaded liposomes by 
MB49 cancer cells at pH 7.4 over time was negligible, confirming that under these 
conditions their colloidal stability and surface charge inhibited the adhesion to the cells 
due to the anionic repulsive charges of pH-RL and cells. On the contrary, at pH 6.5, pH-
RL bound to the cell surface. Even though the cell interaction resulted in limited 
distribution of pH-RL in the cytoplasm, the association of carriers to epithelial cells may 
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represent a valuable advantage for the delivery of therapeutic proteins because it can 
increase their residence time and their local and gradual release.  
The more pronounced and faster pH-RL association to the macrophages with respect to 
the MB49 cancer cells observed at both pHs can be ascribed to the phagocytic activity of 
macrophages. Notably, at acidic pH, the overall association efficiency of the pH-RL with 
macrophages was significantly higher with respect to both neutral conditions and to what 
was observed for bladder cancer cells. Moreover, after a longer exposure time, liposomes 
accumulated in the cytoplasm.  
The intracellular protein delivery and release from this family of carriers can offer 
significant therapeutic advantages by potentiating the activation of immune cells. Indeed, 
the delivery of therapeutic molecules to macrophages by targeted liposomes is a very 
prolific field of investigation for the treatment of a variety of diseases, including cancer 
[29,65]. We recently discovered that a bacterial protein, namely HP-NAP, has a key role 
in driving a T helper (Th) 1 immune response upon binding to the Toll-like Receptor 2 
(TLR2) [67]. Although TLR2 is mainly located on the surface of innate immune cells 
(i.e., macrophages, dendritic cells), an intracellular localization has also been described. 
Macrophages (both the THP-1 cell line [68] and the human-derived macrophages [69]) 
are among the cells where intracellular TLR2 has been found. Dedicated studies are 
required to further elucidate the fate of the liposome-encapsulated therapeutic protein and 
whether it is efficiently released from the phagocytized lipid carriers in its biologically 
active form.  
The bioadhesion to the cells as a result of the surface hydrophobic conversion and 
aggregation of pH-RL at acidic pH was recapitulated in vivo upon instillation of the 
nanocarrier in the mouse bladder. The pH-responsive liposomes at pH 6.5 were 
administered 1 min after pH setting when liposomes were in the non-aggregated state 
(time 0 in Figure 2E). This approach ensured the catheter was not clogged by pH-
responsive liposome aggregates and aggregation takes place within the bladder. This, in 
turn, yielded an efficient delivery of loaded BSA compared to the CL instilled in the 
bladder at the same acidic pH. pH-RL remained associated to the bladder surface even 
after washing, proving that association of the BSA-loaded carrier to the epithelium is 
quite robust. On the other hand, while the BSA-loaded carrier remained localized on the 
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urothelium, we also observed the fluorescent label used to tag liposomes (rhodamine-
DHPE) in the deeper cellular layers of the epithelium, suggesting that partial liposome 
dissociation occurred upon adhesion.  
Bioadhesion is conveyed to drug delivery systems in all the circumstances in which a 
prolonged contact with biological surfaces is desired to increase the local site exposure to 
the loaded drug [70]. According to the evidence, the combination of the 
hydrophobic/neutral conversion of the liposome surface and their macroscopic 
aggregation under the bladder acidic conditions control the deposition of the carrier on 
the bladder surface, thus enhancing the protein disposition in bladder tissue.  
 
5. Conclusions 
The results reported in this work show that the decoration of BSA-loaded liposomes with 
the pH-responsive polymer stearoyl-PEG-polySDM provides a vehicle that efficiently 
associates with and delivers the protein payload to cancer cells and macrophages under 
conditions mimicking the bladder environment. This “smart” nanocarrier represents a 
proof-of-concept, and it has been explored for the delivery of biologics to the bladder 
epithelium. While the liposomes are colloidally stable at neutral pH, they are “activated” 
when exposed to the acid environment of the bladder, yielding epithelium adhesion. The 
liposome adhesion to the urothelium would ensure enhanced protein disposition at this 
site as well as interaction with macrophages that are involved in the control cancer 
growth, offering a clear advantage for bladder cancer therapy. 
Recently, proteins from bacteria have been shown to remarkably inhibit bladder cancer 
growth in vivo due to the specific activation of macrophages. However, these proteins 
require proper delivery strategies to ensure adequate urothelium exposure upon local 
administration.  
On-going studies are investigating the therapeutic effect of pH-RL loaded with 
immunostimulating proteins for the treatment of bladder cancer using an ectopic tumour 
model. Detailed investigations will elucidate the mechanism of action and the 
immunostimulating potency of the biotherapeutic loaded pH-RL with respect to the 
unformulated proteins. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Acknowledgements 
We acknowledge the University of Padova for financial support through the “Progetto di 
Ricerca di Ateneo” (grant N° CPDA121714; CUP C94H12000020005) funding schemes. 
MdB was supported by "Associazione Italiana per la Ricerca sul Cancro/Fondazione 
Cariparo" and "Progetti di Ricerca di Ateneo" (grant N° CPDA137871). MVC was 
recipient of a research fellowship granted by “Fondazione Cariplo” (grant N° 2011-
0485). 
 
 
References 
 
[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global 
cancer statistics, 2012, CA: a Cancer Journal for Clinicians. 65 (2015) 87–108.  
[2] S.F. Shariat, D.C. Chade, P.I. Karakiewicz, D.S. Scherr, G. Dalbagni, Update on 
intravesical agents for non-muscle-invasive bladder cancer, Immunotherapy. 2 
(2010) 381–392.  
[3] D.R. Yates, M. Rouprêt, Failure of bacille Calmette-Guérin in patients with high 
risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an 
update of available treatment options, BJU International. 106 (2010) 162–167.  
[4] D. Lamm, M. Brausi, M.A. O'Donnell, J.A. Witjes, Interferon alfa in the 
treatment paradigm for non–muscle-invasive bladder cancer, Urologic Oncology: 
Seminars and Original Investigations. 32 (2014) 35.e21–35.e30.  
[5] P. Sidaway, Bladder cancer: atezolizumab effective against advanced-stage 
disease, Nat Rev Urol. 13 (2016) 238–238.  
[6] C. Sänger, A. Busche, G. Bentien, R. Spallek, F. Jonas, A. Böhle, M. Singh, S. 
Brandau, Immunodominant PstS1 antigen of mycobacterium tuberculosis is a 
potent biological response modifier for the treatment of bladder cancer, BMC 
Cancer. 4 (2004) 86.  
[7] G. Codolo, M. Fassan, F. Munari, A. Volpe, P. Bassi, M. Rugge, F. Pagano, 
M.M. D'Elios, M. de Bernard, HP-NAP inhibits the growth of bladder cancer in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
mice by activating a cytotoxic Th1 response, Cancer Immunology, 
Immunotherapy. 61 (2011) 31–40.  
[8] D.-S. Hsieh, H. Wang, S.-W. Tan, Y.-H. Huang, C.-Y. Tsai, M.-K. Yeh, C.J. 
Wu, The treatment of bladder cancer in a mouse model by epigallocatechin-3-
gallate-gold nanoparticles, Biomaterials. 32 (2011) 7633–7640.  
[9] C. Mugabe, Y. Matsui, A.I. So, M.E. Gleave, J.H.E. Baker, A.I. Minchinton, I. 
Manisali, R. Liggins, D.E. Brooks, H.M. Burt, In vivo evaluation of 
mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-
muscle-invasive bladder cancer, Clinical Cancer Research. 17 (2011) 2788–
2798.  
[10] E. Bilensoy, C. Sarisozen, G. Esendağlı, A.L. Doğan, Y. Aktaş, M. Şen, N.A. 
Mungan, Intravesical cationic nanoparticles of chitosan and polycaprolactone for 
the delivery of Mitomycin C to bladder tumors, International Journal of 
Pharmaceutics. 371 (2009) 170–176.  
[11] C. Mugabe, P.A. Raven, L. Fazli, J.H.E. Baker, J.K. Jackson, R.T. Liggins, A.I. 
So, M.E. Gleave, A.I. Minchinton, D.E. Brooks, H.M. Burt, Tissue uptake of 
docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and 
their effects on the morphology of the bladder urothelium, Biomaterials. 33 
(2012) 692–703. 
[12] C. Le Visage, N. Rioux-Leclercq, M. Haller, P. Breton, B. Malavaud, K. Leong, 
Efficacy of paclitaxel released from bio-adhesive polymer microspheres on 
model superficial bladder cancer, The Journal of Urology. 171 (2004) 1324–
1329.  
[13] Z. Lu, T.-K. Yeh, M. Tsai, J.L.-S. Au, M.G. Wientjes, Paclitaxel-loaded gelatin 
nanoparticles for intravesical bladder cancer therapy, Clinical Cancer Research. 
10 (2004) 7677–7684.  
[14] Z. Lu, T.-K. Yeh, J. Wang, L. Chen, G. Lyness, Y. Xin, M.G. Wientjes, V. 
Bergdall, G. Couto, F. Alvarez-Berger, C.E. Kosarek, J.L. Au, Paclitaxel gelatin 
nanoparticles for intravesical bladder cancer therapy, The Journal of Urology. 
185 (2011) 1478–1483.  
[15] J.M. McKiernan, L.J. Barlow, M.A. Laudano, M.J. Mann, D.P. Petrylak, M.C. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Benson, A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in 
the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder 
cancer, The Journal of Urology. 186 (2011) 448–451.  
[16] J.W. Johnson, R. Nayar, J.J. Killion, A.C. von Eschenbach, I.J. Fidler, Binding of 
liposomes to human bladder tumor epithelial cell lines: implications for an 
intravesical drug delivery system for the treatment of bladder cancer, Selective 
Cancer Therapeutics. 5 (1989) 147–155.  
[17] D. Christensen, K.S. Korsholm, P. Andersen, E.M. Agger, Cationic liposomes as 
vaccine adjuvants, Expert Review of Vaccines. 10 (2014) 513–521.  
[18] L. Liguori, B. Marques, A. Villegas-Mendez, R. Rothe, J.-L. Lenormand, 
Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins, 
Journal of Controlled Release. 126 (2008) 217–227.  
[19] J. Regberg, A. Srimanee, Ü. Langel, Applications of cell-penetrating peptides for 
tumor targeting and future cancer therapies, Pharmaceuticals. 5 (2012) 991–
1007.  
[20] I. Eue, Growth inhibition of human mammary carcinoma by liposomal 
hexadecylphosphocholine: Participation of activated macrophages in the 
antitumor mechanism, International Journal of Cancer. 92 (2001) 426–433.  
[21] H. Zhuo, Y. Peng, Q. Yao, N. Zhou, S. Zhou, J. He, Y. Fang, X. Li, H. Jin, X. 
Lu, Y. Zhao, Tumor imaging and interferon-γ-inducible protein-10 gene transfer 
using a highly efficient transferrin-conjugated liposome system in mice, Clinical 
Cancer Research. 19 (2013) 4206–4217.  
[22] L. Wang, W. Su, Z. Liu, M. Zhou, S. Chen, Y. Chen, D. Lu, Y. Liu, Y. Fan, Y. 
Zheng, Z. Han, D. Kong, J.C. Wu, R. Xiang, Z. Li, CD44 antibody-targeted 
liposomal nanoparticles for molecular imaging and therapy of hepatocellular 
carcinoma, Biomaterials. 33 (2012) 5107–5114.  
[23] M.S. Muthu, D.T. Leong, L. Mei, S.-S. Feng, Nanotheranostics ˗ application and 
further development of nanomedicine strategies for advanced theranostics, 
Theranostics. 4 (2014) 660–677.  
[24] S. Jain, V. Mishra, P. Singh, P.K. Dubey, D.K. Saraf, S.P. Vyas, RGD-anchored 
magnetic liposomes for monocytes/neutrophils-mediated brain targeting, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
International Journal of Pharmaceutics. 261 (2003) 43–55.  
[25] F. Hajos, B. Stark, S. Hensler, R. Prassl, W. Mosgoeller, Inhalable liposomal 
formulation for vasoactive intestinal peptide, International Journal of 
Pharmaceutics. 357 (2008) 286–294.  
[26] H. Epstein-Barash, D. Gutman, E. Markovsky, G. Mishan-Eisenberg, N. 
Koroukhov, J. Szebeni, G. Golomb, Physicochemical parameters affecting 
liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell 
inhibition, activation of cytokines and complement, and mechanism of cell death, 
Journal of Controlled Release. 146 (2010) 182–195.  
[27] G. Gregoriadis, Liposomes in the therapy of lysosomal storage diseases, Nature. 
275 (1978) 695–696.  
[28] R. Thekkedath, A. Koshkaryev, V.P. Torchilin, Lysosome-targeted octadecyl-
rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase 
in Gaucher’s cells in vitro, Nanomedicine. 8 (2013) 1055–1065.  
[29] A. Nardin, M. Lefebvre, K. Labroquere, O. Faure, J. Abastado, Liposomal 
muramyl tripeptide phosphatidylethanolamine: targeting and activating 
macrophages for adjuvant treatment of osteosarcoma, Current Cancer Drug 
Targets. 6 (2006) 123–133.  
[30] J. Miyazaki, H. Nishiyama, I. Yano, A. Nakaya, H. Kohama, K. Kawai, A. 
Joraku, T. Nakamura, H. Harashima, H. Akaza, The therapeutic effects of R8-
liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma, Anticancer 
Res. 31 (2011) 2065–2071. 
[31] P. Tyagi, M. Kashyap, H. Hensley, N. Yoshimura, Advances in intravesical 
therapy for urinary tract disorders, Expert Opin Drug Deliv. 13 (2016) 71–84.  
[32] J.B. Bassett, J.R. Tacker, R.U. Anderson, D. Bostwick, Treatment of 
experimental bladder cancer with hyperthermia and phase transition liposomes 
containing methotrexate, The Journal of Urology. 139 (1988) 634–636. 
[33] R. Bachor, E. Reich, K. Miller, A. Rück, R. Hautmann, Photodynamic efficiency 
of liposome-administered tetramethyl hematoporphyrin in two human bladder 
cancer cell lines, Urol. Res. 23 (1995) 151–156. 
[34] K.M. Peters, D. Hasenau, K.A. Killinger, M.B. Chancellor, M. Anthony, J. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Kaufman, Liposomal bladder instillations for IC/BPS: an open-label clinical 
evaluation, International Urology and Nephrology. 46 (2014) 2291–2295.  
[35] J. Nirmal, P. Tyagi, M.B. Chancellor, J. Kaufman, M. Anthony, D.D. Chancellor, 
Y.T. Chen, Y.C. Chuang, Development of potential orphan drug therapy of 
intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local 
drug exposure, The Journal of Urology. 189 (2013) 1553–1558.  
[36] J.J. Janicki, M.A. Gruber, M.B. Chancellor, Intravesical liposome drug delivery 
and IC/BPS, Transl Androl Urol. 4 (2015) 572–578.  
[37] B. Kishor, M. Munira, K. Suvarna, K. Swapan, Intravesical drug delivery system 
for bladder: an overview, Ijpcbs. 3 (2014) 680–691. 
[38] S. Bersani, M. Vila-Caballer, C. Brazzale, M. Barattin, S. Salmaso, pH-sensitive 
stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the 
delivery of gemcitabine to cancer cells, European Journal of Pharmaceutics and 
Biopharmaceutics. 88 (2014) 670–682.  
[39] I.F. Tannock, D. Rotin, Acid pH in tumors and its potential for therapeutic 
exploitation, Cancer Research. 49 (1989) 4373–4384. 
[40] C. Rose, A. Parker, B. Jefferson, E. Cartmell, The Characterization of feces and 
urine: a review of the literature to inform advanced treatment technology, Critical 
Reviews in Environmental Science and Technology. 45 (2015) 1827–1879.  
[41] S.-J. Jiang, L.-Y. Ye, F.-H. Meng, Comparison of intravesical bacillus Calmette-
Guerin and mitomycin C administration for non-muscle invasive bladder cancer: 
A meta-analysis and systematic review, Oncol Lett. 11 (2016) 2751–2756.  
[42] M.A. Pérez-Jacoiste Asín, M. Fernández-Ruiz, F. López-Medrano, C. 
Lumbreras, A. Tejido, R. San Juan, A. Arrebola-Pajares, M. Lizasoain, S. Prieto, 
J.M. Aguado, Bacillus Calmette-Guérin (BCG) infection following intravesical 
BCG administration as adjunctive therapy for bladder cancer: incidence, risk 
factors, and outcome in a single-institution series and review of the literature, 
Medicine (Baltimore). 93 (2014) 236–254.  
[43] S. Bersani, S. Salmaso, F. Mastrotto, E. Ravazzolo, A. Semenzato, P. Caliceti, 
Star-Like Oligo-Arginyl-Maltotriosyl derivatives as novel cell-penetrating 
enhancers for the intracellular delivery of colloidal therapeutic systems, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Bioconjugate Chemistry. 23 (2012) 1415–1425.  
[44] A.D. Bangham, M.M. Standish, J.C. Watkins, Diffusion of univalent ions across 
the lamellae of swollen phospholipids, Journal of Molecular Biology. 13 (1965) 
238–IN27.  
[45] J.P. May, M.J. Ernsting, E. Undzys, S.-D. Li, Thermosensitive liposomes for the 
delivery of gemcitabine and oxaliplatin to tumors, Molecular Pharmaceutics. 10 
(2013) 4499–4508.  
[46] M.B. Maeß, B. Wittig, A. Cignarella, S. Lorkowski, Reduced PMA enhances the 
responsiveness of transfected THP-1 macrophages to polarizing stimuli, Journal 
of Immunological Methods. 402 (2014) 76–81.  
[47] X. Xu, A. Costa, D.J. Burgess, Protein encapsulation in unilamellar liposomes: 
high encapsulation efficiency and a novel technique to assess lipid-protein 
interaction, Pharmaceutical Research. 29 (2012) 1919–1931.  
[48] E. Ravazzolo, S. Salmaso, F. Mastrotto, S. Bersani, E. Gallon, P. Caliceti, pH-
responsive lipid core micelles for tumour targeting, European Journal of 
Pharmaceutics and Biopharmaceutics. 83 (2013) 346–357.  
[49] V.A. Sethuraman, K. Na, Y.H. Bae, pH-responsive sulfonamide/PEI system for 
tumor specific gene delivery:  an in vitro study, Biomacromolecules. 7 (2006) 
64–70.  
[50] T. Chanmee, P. Ontong, K. Konno, N. Itano, Tumor-Associated Macrophages as 
major players in the tumor microenvironment, Cancers. 6 (2014) 1670–1690.  
[51] S. Bersani, M. Vila-Caballer, C. Brazzale, M. Barattin, S. Salmaso, pH-sensitive 
stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the 
delivery of gemcitabine to cancer cells, European Journal of Pharmaceutics and 
Biopharmaceutics. 88 (2014) 670–682.  
[52] Y. Nie, L. Ji, H. Ding, L. Xie, L. Li, B. He, Y. Wu, Z. Gu, Cholesterol 
derivatives based charged liposomes for doxorubicin delivery: preparation, in 
vitro and in vivo characterization, Theranostics. 2 (2012) 1092–1103.  
[53] F. Atyabi, A. Farkhondehfai, F. Esmaeili, R. Dinarvand, Preparation of pegylated 
nano-liposomal formulation containing SN-38: in vitro characterization and in 
vivo biodistribution in mice, Acta Pharmaceutica. 59 (2009).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
[54] M. Rovira-Bru, D.H. Thompson, I. Szleifer, Size and structure of spontaneously 
forming liposomes in lipid/PEG-lipid mixtures, Biophysical Journal. 83 (2002) 
2419–2439.  
[55] S. Salmaso, P. Caliceti, Stealth properties to improve therapeutic efficacy of drug 
nanocarriers, Journal of Drug Delivery. 2013 (2013) 374252–19.  
[56] E. Ravazzolo, S. Salmaso, F. Mastrotto, S. Bersani, E. Gallon, P. Caliceti, pH-
responsive lipid core micelles for tumour targeting, European Journal of 
Pharmaceutics and Biopharmaceutics. 83 (2013) 346–357.  
[57] A.J. Reisinger, S.H. Tannehill-Gregg, C.R. Waites, M.A. Dominick, B.E. 
Schilling, T.A. Jackson, Dietary ammonium chloride for the acidification of 
mouse urine, J. Am. Assoc. Lab. Anim. Sci. 48 (2009) 144–146. 
[58] R.A. Fenton, C.-L. Chou, G.S. Stewart, C.P. Smith, M.A. Knepper, Urinary 
concentrating defect in mice with selective deletion of phloretin-sensitive urea 
transporters in the renal collecting duct, Proc. Natl. Acad. Sci. U.S.a. 101 (2004) 
7469–7474.  
[59] J.D. Cook, K.A. Strauss, Y.H. Caplan, C.P. Lodico, D.M. Bush, Urine pH: the 
effects of time and temperature after collection, J Anal Toxicol. 31 (2007) 486–
496. 
[60] B. Roy, P. Guha, R. Bhattarai, P. Nahak, G. Karmakar, P. Chettri, A.K. Panda, 
Influence of lipid composition, pH, and temperature on physicochemical 
properties of liposomes with curcumin as model drug, J Oleo Sci. 65 (2016) 399–
411.  
[61] J. Meyer, L. Whitcomb, D. Collins, Efficient encapsulation of proteins within 
liposomes for slow release in vivo, Biochemical and Biophysical Research 
Communications. 199 (1994) 433–438.  
[62] W. Chanput, J.J. Mes, H.F.J. Savelkoul, H.J. Wichers, Characterization of 
polarized THP-1 macrophages and polarizing ability of LPS and food 
compounds, Food Funct. 4 (2013) 266–276.  
[63] F. Chen, G. Zhang, Y. Cao, M.J. Hessner, W.A. See, MB49 murine urothelial 
carcinoma: molecular and phenotypic comparison to human cell lines as a model 
of the direct tumor response to Bacillus Calmette-Guerin, The Journal of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Urology. 182 (2009) 2932–2937.  
[64] G. Zhao, L.B. Rodriguez, Molecular targeting of liposomal nanoparticles to 
tumor microenvironment, International Journal of Nanomedicine. Volume 8 
(2012) 61–71.  
[65] C. Kelly, C. Jefferies, S.-A. Cryan, Targeted liposomal drug delivery to 
monocytes and macrophages, Journal of Drug Delivery. 2011 (2011) 727241–11.  
[66] N.-B. Hao, M.-H. Lü, Y.-H. Fan, Y.-L. Cao, Z.-R. Zhang, S.-M. Yang, 
Macrophages in tumor microenvironments and the progression of tumors, 
Clinical and Developmental Immunology. 2012 (2012) 1–11.  
[67] M.M. D’Elios, A. Amedei, A. Cappon, G. Del Prete, M. de Bernard, The 
neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune 
modulating agent, FEMS Immunology & Medical Microbiology. 50 (2007) 157–
164.  
[68] H.J. Kang, J.-M. Ha, H.S. Kim, H. Lee, K. Kurokawa, B.L. Lee, The role of 
phagocytosis in IL-8 production by human monocytes in response to lipoproteins 
on Staphylococcus aureus, Biochemical and Biophysical Research 
Communications. 406 (2011) 449–453.  
[69] H. Zhu, Y. Shi, W. Tang, G. Shi, H. Wan, Inhaled corticosteroid influence toll 
like receptor 2 expression in induced sputum from patients with COPD, 
Translational Respiratory Medicine. 1 (2013) 7.  
[70] G.P. Andrews, T.P. Laverty, D.S. Jones, Mucoadhesive polymeric platforms for 
controlled drug delivery, European Journal of Pharmaceutics and 
Biopharmaceutics. 71 (2009) 505–518.  
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Graphical abstract 
 
 
 
 
Protein delivery
Bladder epithelium
Bladder 
cancer cells Macrophages
urine pH
pH sensitive 
coating
Local 
administration
Liposome 
aggregation
Protein 
cargo
